Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

Fecha de publicación: 01/08/2015

Autores de IIS La Fe

Guillermo Sanz Santillana

Autor

Participantes ajenos a IIS La Fe

de Swart L
Smith A
Johnston TW
Haase D
Droste J
Fenaux P
Symeonidis A
Hellström-Lindberg E
Cermák J
Germing U
Stauder R
Georgescu O
MacKenzie M
Malcovati L
Holm MS
Almeida AM
Madry K
Slama B
Guerci-Bresler A
Sanhes L
Beyne-Rauzy O
Luño E
Bowen D
de Witte T

Grupos

Hematología y Hemoterapia

Investigador Principal

Javier De La Rubia Comos

Abstract

Baseline characteristics, disease-management and outcome of 1000 lower-risk myelodysplastic syndrome (MDS) patients within the European LeukaemiaNet MDS (EUMDS) Registry are described in conjunction with the validation of the revised International Prognostic Scoring System (IPSS-R). The EUMDS registry confirmed established prognostic factors, such as age, gender and World Health Organization 2001 classification. Low quality of life (EQ-5D visual analogue scale score) was significantly associated with reduced survival. A high co-morbidity index predicted poor outcome in univariate analyses. The IPSS-R identified a large group of 247 patients with Low (43%) and Very low (23%) risk score within the IPSS intermediate-1 patients. The IPSS-R also identified 32 High or Very high risk patients within the IPSS intermediate-1 patients. IPSS-R was superior to the IPSS for predicting both disease progression and survival. Seventy percent of patients received MDS-specific treatment or supportive care, including red blood cell transfusions (51%), haematopoietic growth factors (58%) and iron chelation therapy (8%), within 2years of diagnosis; while 30% of the patients only required active monitoring. The IPSS-R proved its utility as a more refined risk stratification tool for the identification of patients with a very good or poor prognosis and in this lower-risk MDS population.

Datos de la publicación

ISSN/ISSNe:: 0007-1048, 1365-2141
Tipo:: Article
Páginas:: 372-383
DOI:: 10.1111/bjh.13450
Factor de Impacto:: 2,297 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Smith A:: Epidemiology and Cancer Statistics Group, University of York, York, UK
Johnston TW:: Epidemiology and Cancer Statistics Group, University of York, York, UK
Haase D:: Department of Haematology and Oncology, Georg-August-University of Göttingen, Göttingen, Germany
Fenaux P:: Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris, France
Symeonidis A:: Department of Medicine, Divison of Haematology, University of Patras Medical School, Patras, Greece
Sanz G:: Department of Haematology, Hospital Universitario La Fe, Valencia, Spain
Hellström-Lindberg E:: Department of Medicine, Division of Haematology, Karolinska Institutet, Stockholm, Sweden
Cermák J:: Department of Clinical Haematology, Institute of Haematology & Blood Transfusion, Praha, Czech Republic
Germing U:: Department Of Haematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany
Stauder R:: Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, Austria
Georgescu O:: Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania
Malcovati L:: Department of Haematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Pavia, Italy
Holm MS:: Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
Almeida AM:: Serviço d'Hematologia - Instituto Português de Oncologia de Lisboa, Lisbon, Portugal
Madry K:: Department of Haematology, Oncology and Internal Medicine, Warszawa Medical University, Warszawa, Poland
Slama B:: Service d'Hématologie, Centre Hospitalier d'Avignon, Avignon, France
Guerci-Bresler A:: Service d'Hématologie, Centre Hospitalier Universtaire Brabois Vandoeuvre, Nancy, France
Sanhes L:: Service d'Hématologie, Centre Hospitalier de Perpignan, Perpignan, France
Beyne-Rauzy O:: Service d'Hématologie, Centre Hospitalier Universitaire de Purpan, Toulouse, France
Luño E:: Servicio d'Hematología, Servicio de Salud del Principado de Asturias, Oviedo, Spain
Bowen D:: St. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, UK

Keywords

lower-risk myelodysplastic syndromes; International Prognostic Scoring System; revised International Prognostic Scoring System; co-morbidity score; quality of life score